No Cover Image

Journal article 577 views

The impact of pre-hospital thrombolytic treatment on re-infarction rates: analysis of the Myocardial Infarction National Audit Project (MINAP)

S Horne, C Weston, T Quinn, A Hicks, L Walker, R Chen, J Birkhead, Clive Weston Orcid Logo

Heart, Volume: 95, Issue: 7, Pages: 559 - 563

Swansea University Author: Clive Weston Orcid Logo

Full text not available from this repository: check for access using links below.

Abstract

The objective was to report on rate and predictors of re-infarction following thrombolytic treatment of ST-elevation myocardial infarction (STEMI) in an observational study of 35 356 patients treated by ambulance services and admitting hospitals in England and Wales and entered in the Myocardial Inf...

Full description

Published in: Heart
ISSN: 1355-6037
Published: Heart 2009
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa10010
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract: The objective was to report on rate and predictors of re-infarction following thrombolytic treatment of ST-elevation myocardial infarction (STEMI) in an observational study of 35 356 patients treated by ambulance services and admitting hospitals in England and Wales and entered in the Myocardial Infarction National Audit Project (MINAP) in 2005–6.For 22 391 patients (63.3%) the presence or absence of re-infarction was recorded, and 1460 (6.5%) had re-infarction. Re-infarction rates were 6.5% for reteplase 6.4% for tenecteplase (6.4%); When the pre-hospital treatment to hospital arrival delay was greater than 30 minutes, re-infarction rates were 12.5% for reteplase, and 11.4% for tenecteplase. Re-infarction was more frequent after pre-hospital treatment with tenecteplase than reteplase (9.6% vs 6.6%, p = 0.005). After multivariate analysis independent predictors of re-infarction for tenecteplase were pre-hospital treatment, OR 1.44 (95% CI 1.21 to 1.71, p<0.001) and weight in the highest quartile compared to the lowest, OR 1.66 (95% CI 1.19 to 2.31, p = 0.003). For reteplase neither factor predicted re-infarction. Bleeding was less common with pre-hospital treatment—overall 1.8% against 3.1%; intracerebral bleeding 0.4% against 0.7%.Pre-hospital treatment with tenecteplase was associated with higher re-infarction rates. Longer intervals from pre-hospital treatment to arrival in hospital were associated with high re-infarction rates for both tenecteplase and reteplase.
College: Swansea University Medical School
Issue: 7
Start Page: 559
End Page: 563